Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat people with type 2 diabetes. The drugs, classified as GLP-1 agonists, have also been used for weight loss ... The ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

Ozempic is used to help control blood sugar levels in adults with type 2 diabetes. It is also used to lower the risk of major heart events in people with both type 2 diabetes and heart disease, such ...

or 15 mg, or Ozempic at a dose of 1 mg. At 40 weeks, the mean HbA1c level with Mounjaro at a dose of 5 mg, 10 mg, and 15 mg was reduced by 2.01%, 2.24%, and 2.30%, respectively, compared to a ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...

A nation-wide shortage of Ozempic is impacting people with diabetes ability to access the drug, especially in regional and remote Australia. The Therapeutic Goods Administration says there will be ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within ... class of glucagon-like peptide 1 (GLP-1) medications for diabetes ...